FDA 483 - Ahsan A. Abdulghani, M.D. - August 21, 2023

An FDA inspection of Ahsan A. Abdulghani, M.D. in Turnersville, NJ, revealed significant deficiencies in the conduct of a clinical investigation. Observations included failure to follow the study protocol, maintain accurate and complete case histories, and properly manage investigational drug disposition. These issues raise concerns about data integrity and subject safety during the clinical trial.